XML 54 R43.htm IDEA: XBRL DOCUMENT v3.24.2.u1
Collaborative Arrangements - Daiicho Sankyo - Narrative (Details)
$ in Millions
 3 Months Ended 6 Months Ended
Jun. 30, 2024
USD ($)
Dec. 31, 2023
USD ($)
Jun. 30, 2023
USD ($)
Jun. 30, 2024
USD ($)
Jun. 30, 2023
USD ($)
Oct. 31, 2023
USD ($)
candidate
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]            
Research and development $ 3,500   $ 13,321 $ 7,492 $ 17,597  
Daiichi Sankyo | Collaborative Arrangement, Transaction with Party to Collaborative Arrangement            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]            
Number of antibody drug conjugates obtained right and obligations | candidate           3
Aggregate upfront payments due upon execution in collaborative arrangement           $ 4,000
Refundable upfront payments in collaborative arrangement           1,000
Maximum aggregate contingent milestone payments, per product, in collaborative arrangement           $ 5,500
Research and development $ 65 $ 5,500 $ 0 $ 133 $ 0  
Sales based royalty percentage           5.00%
Daiichi Sankyo | Collaborative Arrangement, Transaction with Party to Collaborative Arrangement | Ifinatamab Deruxtecan            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]            
Refundable upfront payments in collaborative arrangement           $ 500
Daiichi Sankyo | Collaborative Arrangement, Transaction with Party to Collaborative Arrangement | Patritumab Deruxtecan            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]            
Refundable upfront payments in collaborative arrangement           500
Aggregate upfront payments due upon lapse of time in collaborative arrangement           750
Daiichi Sankyo | Collaborative Arrangement, Transaction with Party to Collaborative Arrangement | Raludotatug Deruxtecan            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]            
Aggregate upfront payments due upon lapse of time in collaborative arrangement           $ 750
Liable contracted portion of research and development expenses to incur costs for in collaborative arrangement, percentage           75.00%
Liable contracted portion of research and development expenses to incur costs for in collaborative arrangement           $ 2,000
Daiichi Sankyo | Collaborative Arrangement, Transaction with Party to Collaborative Arrangement | Patritumab Deruxtecan And Raludotatug Deruxtecan            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]            
Aggregate upfront payments due upon lapse of time in collaborative arrangement   $ 1,500